Patents Assigned to GigaMune, Inc.
  • Engineered cells expressing anti-viral T cell receptors and methods of use thereof
    Patent number: 11421220
    Abstract: Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell rectors with specificity against EBV or CMV peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against viral infections.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: August 23, 2022
    Assignee: GigaMune, Inc.
    Inventors: Matthew James Spindler, David Scott Johnson, Ayla Lynn Nelson, Ellen Kathleen Wagner, Adam Shultz Adler, Yoong Wearn Lim, Michael Asensio
  • Recombinant fusion proteins and libraries from immune cell repertoires
    Patent number: 9926554
    Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: March 27, 2018
    Assignee: GigaMune, Inc.
    Inventors: David Scott Johnson, Adam Adler, Rena Mizrahi
  • Recombinant fusion proteins and libraries from immune cell repertoires
    Patent number: 9926555
    Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: March 27, 2018
    Assignee: GigaMune, Inc.
    Inventors: David Scott Johnson, Adam Adler, Rena Mizrahi